Mucosal immunity is our vision,

Infectious diseases, oncology and chronic inflammations our investigation fields,

Innovation our focus !

European Antibody Congress, Basel, Oct31-Nov2

B Cell Design will attend European Antibody Congress in Basel from October 31st to November 2nd.

Read more

Back from San Diego

We are back from San Diego where we attended AACC Clinical Lab Expo

Read more

New scientific articles webpage

A new page with scientific article is available on our website!

Read more

From therapeutic researches to IVD solutions

Our solutions

Mucosal immunity

b-Cell-Design

B Cell Design develops a new mucosal immunotherapy approach for generating a large number of drug and vaccine candidates in infectious field and oncology.
The innovation is based on a genetically modified mouse model (HAMIGA) producing chimeric human IgA. IgA is a class of antibodies particularly involved in the immunity of mucosal area (lung, gut, genital tract, ...) and associated glands (breast, prostate). Because of this characteristic, IgA is a well-adapted tool to develop innovative treatment for both infectious diseases and mucosal cancer.

 

 

Learn more

The antibodies solution

B Cell Design offers to diagnostics companies a reliable, reproducible and secured source of chimeric human antibodies for several purposes:

  • Calibrators, positive controls and quality controls for in vitro diagnostics kits to replace human disease state plasma.
  • Immunocapture antibodies to replace mice antibodies which triggers false positives or negatives due to HAMA antibodies.
  • Research reagents (development or renewal of diagnostic kits, improvment of the products portfolio…)

 

 

Learn more

Our expertise

B Cell Design focuses on mucosal immunotherapy which led B Cell Design to develop two groundbreaking drug candidates:

  • A vaccine candidate in infectious diseases field: a worldwide patented HIV vaccine (A new non-HIV vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against HIV infection – Europe Patent 14305174.6) to prevent or even cure HIV infections. Preliminary studies showed that this approach elicits an efficient local immune response, neutralizing HIV infection of human cells.
  • A drug candidate in oncology field (colorectal cancer) for immunotherapy, radioimmunotherapy applications or medical imaging.


ArkAb, internal division of B Cell Design, is dedicated to the in vitro diagnostics market. Through its patented technology (HAMIGA, GAMMAPRIM, INEPS), B Cell Design develops and manufactures human chimeric antibodies to replace human disease state plasma currently used as calibrators, positive controls and quality controls.